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Approach to device-detected 
subclinical atrial fi brillation
DEVICE-
DETECTED AF
ABSTRACT
Subclinical atrial fi brillation, a commonly encountered 
entity in patients with implantable devices, has been 
associated with a number of adverse outcomes – the 
most important of which is thromboembolism. Through 
the detection of atrial high rate episodes, implanted 
devices offer a method to monitor for atrial fi brillation 
over extended periods of time. Several studies have 
demonstrated that patients with device-detected atrial 
tachyarrhythmias have an increased incidence of stroke, 
especially in the presence of additional risk factors. 
Yet, there are many uncertainties with limited evidence 
from randomised clinical studies and no formal guide-
lines to inform management in this population. This 
contributes to marked practice heterogeneity, under-
recognition and missed opportunities for stroke pre-
vention. We propose a logical approach to manage-
ment of patients with device-detected atrial high rate 
episodes pending additional data from ongoing trials. 
SAHeart 2017;14:86-95
INTRODUCTION
Cardiac implantable electronic devices (CIEDs) are becoming 
more and more common due to an aging global population 
and expanded criteria for implantation. During 2009, over 1.3 
million new or replaced implantable cardiac devices were 
implanted worldwide, with around a quarter of these occur-
ring in the United States (US) alone.(1,2) South Africa has 
experienced substantial growth with an almost 25% rise in 
CIEDs implanted between 2005 and 2009, as opposed to only 
8% in the US.(1) In addition, there is a greater availability of 
external surface monitoring and implantable loop recorders 
(ILR). Out of this vast increase in continuous arrhythmia 
monitoring arises the challenge of how to approach the 
abundance of data that identifies subclinical arrhythmia, and 
germane to this discussion, atrial fibrillation (AF).
As the most pervasive sustained arrhythmia encountered in 
clinical practice, AF has risen in age-adjusted incidence over 
the last half century – a trend which may be plateauing over 
the last decade.(3,4) After age 40 the lifetime risk of developing 
AF is almost 1 in 4.(2) As many as 40% of patients are entirely 
asymptomatic – also termed subclinical AF – and the arrhythmia 
may only come to the attention of the patient and provider as 
an incidental finding.(5) Population screening of those over 65 
years of age would detect subclinical AF in an estimated 1.4% 
of patients – of whom, more than two thirds would be at high 
risk for stroke based on clinical risk prediction models.(6) AF 
shares many risk factors – including age, male gender, heart 
failure and coronary disease – with indications for a permanent 
pacemaker or implantable cardioverter defibrillator (ICD) and, 
as such, the detection of clinically silent paroxysms of AF by 
device interrogation is not uncommon. In patients with CIEDs 
placed for unrelated indications, without a prior history of 
permanent AF, 43% had 5 minutes or more of AF detected 
over 2 years of follow-up in a pooled analysis of 5 large 
prospective trials (n=10 016).(7) Therefore, adoption of a 
strategy for dealing with device-detected subclinical AF is vital 
for clinicians.
In the midst of several studies which demonstrate the con-
sequences of device-detected AF, many uncertainties currently 
exist regarding its management. Is device-detected AF asso-
ciated with the same stroke risk as AF diagnosed by conventional 
means? Is the presence of device-detected AF enough to 
warrant oral anticoagulation (OAC) or do additional stroke 
risk factors need to be taken into account? Should OAC be 
given continuously or is it safe to interrupt treatment during 
periods of sinus rhythm? What threshold of device-detected 
AF should prompt initiation of OAC and should this first be 
confirmed by surface monitoring? Does OAC reduce the risk 
of thromboembolic events in patients with subclinical device-
detected AF? In addition to elaborating on the available evi-
dence, this review also highlights what remains unknown and 
warrants further study. 
Martin van Zyl, Christopher J. McLeod and Bernard J. Gersh
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, 
Minnesota, United States of America
Address for correspondence: 
Martin van Zyl
200 First Street SW
Rochester
Minnesota
United States of America
55905
  
Email: 
vanzyl.martin@mayo.edu
87
20
17
Vo
lu
m
e 
14
 N
um
be
r 2
ATRIAL FIBRILLATION AS A VASCULAR 
DISEASE
In order to convey the clinical relevance of device-detected 
atrial fibrillation, an overall understanding of the pathobiology 
and potential consequences of AF in general is important. 
Although probably not the only mechanism, AF has classically 
and conceptually been associated with an elevated risk of 
ischaemic stroke through a stasis-induced formation of throm-
bus in the left atrial appendage (LAA) which may dislodge and 
embolise to the central nervous system. Subsequently, several 
observations have suggested that additional mechanisms may 
be at work when considering AF as a marker of risk, for not 
only stroke, but a wide range of vascular outcomes.(8) A large 
meta-analysis involving over half a million patients with AF over 
a median follow-up period ranging from 3 - 6 years, highlights 
that this arrhythmia is associated with increased absolute risk of 
heart failure (11.1 events/1 000 person-years), chronic kidney 
disease (6.6/1 000), stroke (3.6/1 000) and ischaemic heart 
disease (1.4/1 000) as well as excess cardiovascular (2.6/1 000) 
and all-cause mortality (3.8/1 000).(9) Certainly this association 
does not imply direct causality but it does question why a 
correlation with excess mortality and morbidity from both 
cardiovascular and non-cardiovascular causes exists.
Although the exact pathophysiology is complex, atrial 
remodeling with dilatation and fibrosis is a central feature 
underlying longstanding AF. Atrial ischaemia, hypertension, 
diabetes mellitus, systemic inflammation, hypertension, valvular 
disease and senescence can all contribute to atrial stretch, 
dilatation and injury. Atrial myocyte apoptosis leads to activa-
tion of fibroblasts via several mediators (including calpain, 
angiotensin II and transforming growth factor beta-1) resulting 
in collagen deposition and fibrosis.(8) Genomic studies have 
also identified genetic variants associated with a susceptibility 
for primary atrial fibrosis.(10) Atrial fibrosis disrupts diastolic 
function and electrical conduction. The chamber becomes pre-
disposed to electrical reentry and anisotropy which then 
permits ectopy and irregular wave fronts.(11) Successful surgical 
ablation of AF does not eradicate progression of fibrosis, 
suggesting that the process occurs irrespective of the presence 
of arrhythmia.(12) Impairment in diastolic function leads to 
increased left atrial (LA) volume which, in turn, has been 
independently associated with an increased risk of myocardial 
infarction, congestive heart failure, coronary revascularisation 
and stroke.(13,14)
Yet many of these variables which contribute to LA fibrosis are 
also associated with an increased risk of cardiovascular disease 
in general and AF may simply be a surrogate marker of vascular 
disease burden. This is supported by the finding that AF in 
the absence of other risk factors for stroke in patients under 
60 years of age, otherwise referred to as lone AF, does 
not significantly increase stroke risk or overall mortality.(15,16) 
Furthermore, in patients with additional stroke risk factors, the 
risk remains elevated with paroxysmal AF even when in sinus- 
or paced-atrial rhythms.(17-19) The PREVAIL (WATCHMAN 
LAA closure device in patients with atrial fibrillation vs. long 
term warfarin therapy) trial was designed to follow-up on 
the positive data of PROTECT AF (WATCHMAN left atrial 
appendage system for embolic PROTECTion in patients with 
atrial fibrillation) – and with failure to meet non-inferiority over 
18 months has also brought into question the long-term efficacy 
of percutaneous LAA closure devices in stroke pre-vention 
without systemic anticoagulation.(20) Also to be considered, 
the LA cavity rather than the appendage can be the site of 
thrombus formation in more than half of patients with valvular 
AF and 1 in 9 with nonvalvular AF.(21) 
Endothelial dysfunction, systemic inflammatory response and 
atrial hypocontractility as cause and consequence of a fibrotic 
atrial cardiomyopathy have been implicated as the drivers of 
a hypercoagulable state in AF.(8) These factors do not abate in 
the absence of arrhythmia and advocate that AF, whether 
persistent or paroxysmal, could itself be viewed as a vascular 
disease (Figure 1). Considering these basic principles is crucial 
when formulating an approach to device-detected AF.
INTERPRETATION OF DEVICE-DETECTED 
ATRIAL TACHYARRHYTHMIAS 
Device-detection of subclinical AF may occur intentionally – for 
example, via cardiac monitoring following cryptogenic stroke – 
or incidentally as a result of cardiac monitoring for an unrelated 
indication. Various methods exist for detecting subclinical atrial 
tachyarrhythmias including ambulatory surface monitoring and 
CIEDs (ILRs, pacemakers and ICDs). Unlike pacemakers or 
ICDs which rely on one or more transvenously implanted 
leads to sense, the subcutaneous ILR records cardiac signals 
transmitted through the chest wall. Significant advantages of 
implantable devices are the ability to perform long-term 
continuous monitoring and improved compliance – the latter 
of which can be less than 50% with prolonged ambulatory 
surface monitoring, even in the setting of a clinical trial.(22) The 
obvious disadvantages of implantable devices include cost, the 
need for a minimally-invasive procedure and data fatigue with 
an abundance of information recorded over extended periods 
of time.
Historically, leadless ILRs and single-chamber pacemakers only 
had the ability to detect AF using irregular and incoherent R-R 
intervals. When compared to simultaneous external Holter 
monitor recordings in patients with known paroxysmal AF, 
these algorithms falsely classified AF resulting in suboptimal 
specificities of around 85% while retaining a sensitivity of over 
95%.(23) False positives occurred as a result of premature atrial 
or ventricular complexes, irregular sinus rhythm, ventricular 
bigeminy and other atrial arrhythmias. Newer generation 
leadless devices have an AF detection algorithm which can filter 
P waves in order to reduce false positives by 46%, thereby 
raising both specificity and sensitivity to around 97%.(24)
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In devices with atrial sensing capability, such as dual-chamber 
permanent pacemakers, detection of an atrial high rate episode 
(AHRE) is often used as a surrogate for atrial tachyarrhythmia 
and AF. Modern devices may automatically identify and store 
these events as atrial flutter or fibrillation depending on 
whether or not the rhythm is regular or irregular, respectively. 
Sensitivity for AF with device AHRE algorithms is high; ranging 
from 94% - 100%.(25-27) False negatives, although uncommon, 
primarily occur with AF of durations of less than 30 seconds 
and occasionally with misclassification of short duration AF 
to atrial flutter, sinus tachycardia or premature atrial com-
plexes.(26,27) As discussed later in this review, the clinical 
significance of short duration AF episodes remains uncertain.
Using device-detected AHREs to diagnose AF is imperfect. Of 
almost 6 000 AHREs (>190 beats per minute for >6 minutes), 
17% were false positives when intracardiac electrograms were 
reviewed independently by researchers in the Asymptomatic 
AF and stroke evaluation in pacemaker patients and the AF 
reduction atrial pacing trial (ASSERT) of 2 580 patients.(28) False 
detections occur as a consequence of far field oversensing of 
R waves, retrograde ventriculoatrial conduction, noise and 
frequent atrial ectopy.(28-30) As such, adjudication by a qualified 
clinician remains essential prior to making a diagnosis of AF 
based on device interrogation data.
Storing electrograms reduces the battery life of devices and 
may be limited by device memory. In some cases, this infor-
mation may not be available requiring an alternate means of 
discriminating between true and false AF detection. The most 
recent guidelines from the European Society of Cardiology 
(ESC) provides a class IB recommendation for further electro-
cardiogram (ECG) monitoring to confirm AF in all patients 
found to have an AHRE.(31) Duration and timing of an AHRE 
may also help discriminate. In the ASSERT trial, positive 
predictive value for AF increased from 83% - 97% when the 
duration threshold of AHREs was increased from 6 minutes to 
6 hours at >190 beats per minute.(28) Hence, in the case of 
long duration AHREs, further investigation is unlikely to 
improve diagnostic accuracy. After the first 12 months, new 
inappropriate detections were also rare (3%) over nearly 2 
years of additional follow-up.(28) This data would suggest that 
short AHREs, lasting less than 6 hours within the first 12 
months following device placement, requires further con-
DEVICE-DETECTED AF
FIGURE 1:  Postulated association between atrial fi brillation and vascular disease. Vascular infl ammation and injury result in an atrial 
myopathy with dilatation, fi brosis and endothelial dysfunction. The presence of atrial fi brillation acts as a marker of vascular disease burden.
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firmation of AF either by review of available electrograms, 
reprogramming of devices to allow storing of electrograms 
during AHREs or with an additional ECG monitoring modality, 
such as Holter.
THE RELATIONSHIP BETWEEN STROKE AND 
DEVICE-DETECTED ATRIAL FIBRILLATION
Several trials have demonstrated an association between 
device-detected AHREs and elevated stroke risk. The first large 
scale study to demonstrate this was a sub group analysis 
published in 2003 of 312 patients from the landmark mode 
selection trial (MOST) of dual-chamber vs. single-chamber 
pacing in patients with sinus node dysfunction. Over a mean 
of 27 months, 51% of patients from this sub group had at least 
one device-detected AHRE (>220 beats/minute for 10 
consecutive beats) lasting longer than 5 minutes. These AHREs 
were not adjudicated to confirm AF and one-third of these had 
confirmed AF prior to development of an AHRE. Nonethe-
less, the presence of an AHRE was associated with a near 3-fold 
increase in composite end-point of death or stroke and a 
6-fold increase in AF diagnosis.(25)
To follow-up on the previous association, the relationship 
between daily atrial tachyarrhythmia burden from implantable 
device diagnostics and stroke risks study (TRENDS) enrolled 
over 2 000 patients with CIEDs and at least 1 stroke risk factor 
in an observational prospective trial. Over a mean follow-up of 
1.4 years, a quarter of patients had an AHRE detected (defined 
as >120 beats/minute for ≥20 minutes). Patients were twice 
as likely to sustain a stroke or TIA within 30 days with a maxi-
mum daily AHRE burden of at least 5.5 hours compared to 
those without AHRE. Interestingly, and in contrast to the MOST 
study, an AHRE burden of less than 5.5 hours but more than 
5 minutes per day exhibited no significant difference when 
compared to those with a zero burden. This trial, however, 
had included patients with prior AF and AHREs were not 
adjudicated. Furthermore, the study entailed limited follow-up 
and a small number of outcome events.(32)
Subsequently, the landmark ASSERT trial was primarily designed 
to investigate the association between AHRE and stroke 
incidence by prospectively analysing more than 2 500 CIED 
patients over the age of 65 with hypertension. In contrast to 
TRENDS, patients with a previous history of atrial tachy-
arrhythmias were excluded and intracardiac electrograms were 
adjudicated to confirm AF for each AHRE. At least 1 AHRE 
(defined as ≥190 beats/minute lasting greater than 6 minutes) 
was detected in a tenth of patients at 3 months and in more 
than a third of patients over a median follow-up of 2.5 years. 
Subclinical AF was recognised as being 8 times more common 
than clinical AF. Subclinical AHREs, detected during the first 
3 months, were independently associated with a 2.5-fold 
increased risk of ischaemic stroke or systemic embolism, even 
when adjusted for baseline stroke risk factors. In ASSERT, both 
longer AHRE duration and higher number of episodes were 
associated with an increased risk of thromboembolism. Hazard 
ratios were 2, 3 and 5 for AHRE durations of >6 minutes, >6 
hours and >24 hours, respectively.(33)
RISK STRATIFICATION IN PATIENTS WITH 
DEVICE-DETECTED ATRIAL FIBRILLATION
The critical threshold AHRE duration associated with an 
increased stroke risk varied greatly from trial to trial: >5 minutes 
in MOST, >6 minutes in ASSERT and >5.5 hours cumulative 
daily in TRENDS.(25,32,33) The variability stems from differences 
in study technique and technical parameters including adjudi-
cation to confirm AF, AF detection algorithm, length of follow-
up, baseline stroke risk and sample size. A pooled analysis was 
aimed at determining the effect of AHRE burden on stroke risk. 
The Stroke prevention Strategies based on Atrial Fibrillation 
information from implanted devices (SOS AF) study included 
5 prospective studies (including TRENDS) and cumulatively 
involved over 10 thousand patients. An AHRE lasting 5 minutes 
or more occurred in 43% of patients during the median follow-
up of 24 months. An increased risk of ischaemic stroke was 
significantly associated with a maximum daily AHRE threshold 
of ≥5 minutes (hazard ratio 1.76, p=0.04) but the highest risk 
was found with ≥1 hour (hazard ratio 2.11, p=0.008). When 
controlling for CHADS2 (congestive heart failure, hyperten-
sion, age ≥75 years, diabetes mellitus, stroke or transient 
ischaemic attack) score risk factors and oral anticoagulation 
used at baseline, the hazard ratio remained elevated at almost 
2 (p=0.049) for a burden of ≥1 hour compared to <1 hour. 
The authors concluded that, when AHRE burden was assessed 
as a continuous variable, every additional hour increase led to a 
3% increase in the relative risk for stroke or TIA.(7) Similarly, a 
recently published reanalysis of ASSERT data found that, even 
when controlling for other stroke risk factors (age, sex, BMI, 
heart failure, prior stroke, diabetes and arterial disease) a 
continuous AF burden of more than 24 hours was associated 
with increased risk of stroke or systemic embolism (hazard ratio 
3.24, p=0.003) with no significant difference when comparing 
shorter durations to no AF.(34) Higher AF burden appears to be 
associated with higher risk of stroke, at least in part due to the 
finding that longer duration AHREs have a higher positive 
predictive for true AF.(28)
Risk stratification using clinical risk prediction scores for patients 
with device-detected AF has been studied. Data from the SOS 
AF trial suggested that AF burden was predictive of stroke, 
even in patients with a low CHADS2 score.(7) In the ASSERT 
trial, the absolute risk of stroke approached a rate of nearly 
4% in the presence of AF with a CHADS2 score of greater 
than 2 but with lower CHADS2 scores there were no signifi-
cant association.(33) In a separate retrospective study, data 
from remote CIED interrogation in over 500 patients was 
retrospectively analysed over a follow-up period of 1 year. 
Patient risk was categorised based on CHADS2 score in addition 
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to a minimum AHRE burden over a 1 day period (Figure 2). 
High risk patients had 24 hours of AHRE burden and a CHADS2 
score of 1, >5 minutes and a CHADS2 score of 2, or a CHADS2 
score of >2. Patients with a CHADS2 score of 0 were found 
to be low risk regardless of burden; however, this conclusion 
was limited by short follow-up and a low incidence of out-
come thromboembolic events (2.5% in total).(35)
Interestingly, the annual stroke rates for AF patients with a 
CHADS2 score of 2 were lower (around 2%) in ASSERT and 
other device-detected AF trials than the 4% found in the 
national registry of atrial fibrillation (NRAF) trial which originally 
validated this clinical risk prediction score in 2001.(33,35,36) The 
NRAF validation trial has been criticised for including high risk 
patients with a high prevalence of congestive heart failure as 
well as prior stroke and TIA, thereby skewing the com-
parison.(37) This finding may also reflect the reduction in stroke 
incidence in developed countries over the last decade and that 
neither trial controlled for anticoagulation use at baseline.(38) 
Nonetheless, the available data suggests that in the device-
detected AF population – similar to those with AF detected 
through other modalities – clinical risk prediction scores are 
most helpful at the extremes with uncertainty surrounding the 
intermediate scores.
It is crucial to recognise though, that no clear temporal 
relationship between stroke and device-detected AHRE has 
been established in the majority of studies. In a sub group 
analysis of TRENDS: only half of those who experienced a 
stroke or TIA had an AHRE episode recorded prior to the 
event; a quarter were linked to an AHRE within a month of the 
event and only 15% were associated with an AHRE during the 
event.(17) Findings were very similar with the ASSERT data: 
only half of the patients sustained AF prior to their thrombo-
embolic stroke event; only 12% within 30 days and only a single 
patient (2%) during the event.(18) Furthermore, none of the 
patients in this study sustained AF lasting longer than 24 hours 
continuously; recognising that current consensus opinion and 
anticoagulation guidelines are predicated on a minimum dura-
tion of 48 hours of AF as the requisite duration for intra-atrial 
thrombus formation.(18,39) As alluded to previously in this 
review, temporal dissociation suggests that a mechanism 
beyond pure cardiogenic thromboembolism may play a role 
in stroke in some AF patients, particularly among those with 
additional risk factors.
A temporal association was, however, demonstrated in an 
observational study involving nearly 10 000 patients in the US 
Veterans dministration with CIEDs of which 187 suffered an 
ischaemic stroke. An AF burden of 5.5 hours within a day was 
not met by the majority (85%) in the 30 days before stroke, yet 
a small subset of 13 patients (7%) did have a positive AF burden 
in the 30 days before stroke. This conferred an odds ratio for 
stroke of more than 17 (p <0.0001) for the first 5 days after 
onset of AF which gradually returned to 1 as the period reached 
beyond 30 days.(40)
The majority of studies had classified patients with AHREs 
lasting less than 5 minutes as having no AF and potential exists 
for missing clinically important events in this group. Recently 
published data from the RATE registry (registry of atrial 
tachycardia and atrial fibrillation episodes) – a multicentre 
prospective observational study aimed at following outcomes 
of over 5 000 patients with device-detected AF of any dura-
tion – demonstrated that short episodes of AF terminating 
within a single adjudicated electrogram (usually less than 20 
seconds) did not increase the risk of a composite outcome of 
stroke, TIA, hospitalisation or mortality. Importantly, approxi-
mately one half of these patients did go on to develop longer 
episodes of AF over 2 years of follow-up. Longer episodes 
were associated with a hazard ratio of 1.5 (p=0.03) for stroke 
or TIA and 1.7 (p<0.001) for the composite outcome.(41) These 
results suggest that very brief AHREs may not be clinically 
significant in isolation but, given a propensity for these patients 
to have longer episodes over time, close surveillance remains 
important. Furthermore, whether multiple shorter events are 
clinically equivalent to a single longer event of a similar cumu-
lative duration and whether events longer than 20 seconds but 
less than 5 minutes in duration are clinically significant when 
compared to no events has yet to be determined.
AF = Atrial Fibrillation, CHADS2 = Congestive heart failure, Hypertension, Age ≥75 
years, Diabetes Mellitus, Stroke or transient ischaemic attack.
FIGURE 2: Thromboembolic risk stratifi ed by atrial 
fi brillation duration and CHADS2 score. Combination of 
AF burden and CHADS2 score separated the study population 
into 2 groups with signifi cantly different thromboembolic risk 
(0.8% vs 5.0%). Columns correspond to CHADS2 scores and 
rows correspond to AF duration over the course of 1 day (none, 
>5min, and 24h continuous). 
Reprinted with permission from Botto, et al.(33)
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CURRENT CLINICAL PRACTICES FOR DEVICE-
DETECTED ATRIAL FIBRILLATION
At present, there is limited evidence from randomised clinical 
studies to inform management of subclinical AF detected by 
CIEDs. The topic was only recently included in guidelines 
released by the ESC but remains absent from North American 
consensus statements. This stems from ambiguity regarding 
stroke risk stratification with regards to accuracy of AF 
detection, burden of AF, individual stroke risk and validity of 
clinical risk prediction scores such as CHADS2 or CHA2DS2-
VASc (congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, stroke or transient ischaemic attack, vascular 
disease, age 65 - 74, female sex category) in this patient 
population.(36) Therefore, the approach to device-detected AF 
varies greatly between clinicians.
A European Heart Rhythm Association survey involving 46 
primarily medium-high volume European device-implanting 
centres captured the current practice heterogeneity (Figure 3). 
When presented with a patient scenario where a single AHRE 
was detected lasting more than 6 minutes, 53% of cardiologists 
recommended anticoagulation when CHA2DS2-VASc score 
was 2 - 3 as opposed to 70% when CHA2DS2-VASc was 4. 
Overall, a trend was shown towards favouring anticoagulation 
in patients with higher CHA2DS2-VASc scores, multiple AHREs 
and longer duration episodes.(42)
In the setting of recent stroke, data from randomised trials 
suggests a higher likelihood of OAC prescription patterns in 
patients with device-detected AF. In the landmark cryptogenic 
stroke and underlying AF (CRYSTAL AF) trial, the number of 
patients on OAC at 6 and 12 months was more than double in 
a group randomised to receive an ILR following stroke when 
compared to controls who received monitoring by conven-
tional strategies (pulse palpation, ECG, Holter or event 
monitors). At 12 months, 97% of patients with device-detected 
AF were receiving OAC at 12 month follow-up, despite the 
study protocol not mandating treatment of AF.(43) Although 
providers may recognise the importance of secondary stroke 
prevention, the potential for primary prevention from device-
detected subclinical AF may still be underappreciated. In a 
retrospective study of 445 patients with CIEDs, 53% had 
device-detected AF but, in those without a history of clinical 
AF, less than one-quarter were prescribed OAC despite 88% 
having a CHADS2 score of 1 or more. Patients with clinical 
AF were more than twice as likely to receive OAC.(44) These 
findings suggest that a more unified approach towards 
management of device-detected AF for primary prevention is 
required.
An open-label prospective multicentre study is currently under-
way which aims to implant an ILR in patients at high risk for 
AF in order to understand how patients with device-detected 
AF are managed. The REVEAL AF trial (NCT01727297) plans 
to follow 400 patients for a minimum of 18 months to assess 
time to first episode of AF lasting more than 6 minutes, clinical 
predictors for AF, and observations of physician actions in 
response to awareness of AF. 
AHRE = Atrial High Rate Episodes, AF = Atrial Fibrillation CHA2DS2-VASc = Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Stroke or transient ischaemic 
attack, Vascular disease, Age 65 - 74, female Sex category.
FIGURE 3: Physician recommendation of anticoagulation for 4 scenarios. (A) CHA2DS2-VASc score of 2-3, single AHRE. 
(B) CHA2DS2-VASc score of 2-3, multiple AHRE’s. (C) CHA2DS2-VASc score of 4, single AHRE. (D) CHA2DS2-VASc score of 4, multiple AHRE’s. 
Reprinted with permission from Todd, et al.(40) 
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MANAGEMENT STRATEGIES AND STROKE 
PREVENTION IN DEVICE-DETECTED ATRIAL 
FIBRILLATION: EXISTING EVIDENCE
Currently, limited data exits to support the use of OAC in 
subclinical AF. An observational study from the UK involving 
more than 5 000 patients visiting outpatient clinics for reasons 
unrelated to AF, those with an incidental first AF diagnosis 
demonstrated more than double the stroke rate and all-cause 
mortality rate when matched to controls without AF. Of these 
patients, nearly half received OAC during follow-up and 
experienced a significant reduction in both stroke (by two-
thirds) and all-cause mortality (by one-third).(45) As such, OAC 
has been shown to be effective at reducing stroke even in 
those with incidentally-diagnosed subclinical AF, but not 
necessarily in those with AF detected by an implanted device.
A single randomised prospective trial with several principal 
flaws has been published which evaluated OAC in device-
detected AF. The highly controversial premise of intermittent 
anticoagulation stems from the hypothesis that patients who 
are free from AF for a period of time could safely stop their 
OAC due to a presumed temporal reduction in stroke risk. 
The randomised trial of anticoagulation guided by remote 
rhythm monitoring in patients with implanted cardioverter-
defibrillator and resynchronisation devices (IMPACT) was 
primarily aimed at utilising remote monitoring to guide inter-
mittent anticoagulation in almost 3 000 patients with dual-
chamber or biventricular ICDs. The trial was terminated pre-
maturely due to a lack of benefit of intermittent anticoagulation 
with regards to thromboembolism, hemorrhagic stroke, major 
bleeding and mortality.(46) Several limitations may have con-
tributed to the results of this study. An AHRE duration 
threshold of 24 hours was used to initiate OAC in the 
intervention group when much shorter durations have been 
associated with significant stroke risk in other studies.(25,32,33,35) 
Finally, this trial also preceded many of the studies that have 
demonstrated a temporal dissociation between AHRE and 
thromboembolism; notably, a third of AHREs were detected 
only after the event in this investigation. The provocative 
conclusion of this trial and the concern from opponents of 
intermittent OAC use is that the presence of AHRE is a 
marker of risk rather than the direct cause of thromboembo-
lism – arguing for maintenance of therapeutic anticoagulation 
without interruption in all at risk individuals.(46) 
Which patients will benefit most from OAC has yet to be 
determined by a randomised trial. The CRYSTAL AF study did 
demonstrate improved OAC prescription for secondary 
prevention in those patients with devices, and although not 
powered to detect this end point, demonstrated a trend 
towards lower recurrent stroke and TIA in the device group 
when compared to controls utilising conventional monitoring 
(5% vs. 9%).(43) Three trials are currently recruiting to evaluate 
efficacy of OAC in stroke prevention of patients with device-
detected AF: subclinical atrial fibrillation and stroke (SILENT – 
NCT02004509), Non-vitamin K antagonist oral anticoagulants 
in patients with atrial high rate episodes (NOAH – 
NCT02618577) and apixaban for the reduction of thrombo-
embolism in patients with device-detected sub-clinical atrial 
fibrillation (ARTESiA – NCT01938248). To initiate OAC in 
the intervention groups, SILENT will use a threshold AF burden 
of >5.5 hours with ARTESiA and NOAH planning to use >6 
minutes. An additional 2 randomised studies will attempt to 
reanalyse the safety of intermittent OAC in patients with 
various AF burdens and CHADS2 scores: Safety study on 
stopping anticoagulation medication in patients with a history 
of atrial fibrillation (TACTIC AF – NCT 01650298) and rhythm 
evaluation for anticoagulation with continuous monitoring 
(REACT.COM – NCT01706146).
In patients with contraindications to systemic anticoagulation, 
LAA appendage occlusion and ligation for stroke prevention 
could potentially be considered, yet the risk-benefit ratio will 
need to be scrutinised for these invasive procedures.(20)
Attempt to document 
AF by surface ECG 
monitoring
Discuss benefits and 
risks of anti-
coagulation with 
patient – threshold for 
initiation of 
anticoagulation may 
be lower in patients at 
high stroke risk or with 
higher AHRE burden 
(ex. >24 hours)
Review device 
electrograms during 
episodes
Initiate AF 
management including 
anticoagulation if 
appropriate based on 
clinical risk prediction 
models (ex. CHADS2)
Follow device data to 
relate symptoms and 
guide rate and rhythm 
control strategy
Yes No
FIGURE 4:  Proposed approach to patients with atrial 
high rate episodes detected by implanted devices.
AHRE = Atrial High Rate Episode, AF = Atrial Fibrillation.
AHRE detected by an implanted device
Verify presence of AF to establish diagnosis
AF confirmed?
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TABLE 1: A summation of the large prospective trials examining the relationship between device-detected atrial high rate episodes and 
thromboembolic events.
Study 
MOST
TRENDS
ASSERT
IMPACT
SOS AF
RATE
n 
312 patient subgroup with sinus node 
dysfunction and pacemakers programmed to 
log AHRE
2 486 patients with ≥1 stroke risk factors with 
pacemakers or defi brillators
2 580 patients ≥65 years of age with 
hypertension and no history of AF, with 
pacemaker or ICD
2 718 patients with dual-chamber and 
biventricular defi brillators
2-Arm RCT: (1) start and stop anticoagulation 
on the basis of remote rhythm monitoring vs. 
(2) usual offi ce-based follow-up
Pooled analysis of data from 5 prospective 
studies; 10 016 patients with pacemakers and 
ICDs without permanent AF, with at least 3 
months of follow-up
5 379 patients with pacemakers or ICDs
Main fi ndings 
Median follow-up, 2.3 years
The presence of any AHRE was an 
independent predictor of the following: 
Total mortality (HR, 2.48; 95% CI, 1.25-4.91; 
p=0.0092); death or nonfatal stroke (HR, 2.79; 
95% CI, 1.51-5.15; p=0.0011); and atrial 
fi brillation (HR, 5.93; 95% CI, 2.88- 2.2; 
p=0.0001)
Mean follow-up, 1.4 years
Annual thromboembolism risk was 1.1% for 
no-burden, 1.1% for low-burden, and 2.4% for 
high-burden subsets of 30-d windows
Mean follow-up, 2.5 years
Subclinical atrial tachyarrhythmias were 
associated with an increased risk of ischaemic 
stroke or systemic thromboembolism (HR, 
2.49; 95% CI, 1.28-4.85; p=0.007) even after 
adjustment for predictors of stroke (HR, 2.50; 
95% CI, 1.28-4.89; p=0.008)
Median follow-up, 2 years
Primary events (2.4 vs. 2.3 per 100 
patient-years) did not differ between trial arms 
(HR, 1.06; 95% CI, 0.75–1.51; p=0.732);
in patients with AHRE, thromboembolism 
rate was 1.0 vs 1.6 per 100 patient-y 
(p=0.251); no temporal relationship between 
AHRE and stroke was seen
Median follow-up, 2 years
Increased risk of stroke was associated with a 
maximum daily AHRE threshold of ≥5 minutes 
(HR, 1.76; 95% CI, 1.02-3.02; p=0.041) but the 
highest risk was with ≥1 hour (HR, 2.11; 95% 
CI, 1.22-3.64; p=0.008); when controlling for 
stroke risk factors and oral anticoagulation use 
at baseline, the risk persisted (HR, 1.90; 95% 
CI, 1.00-3.61; p=0.0487)
Median follow-up, 1.9 years
Patients with only short AHREs were 
associated with lower adjusted incidence of 
composite clinical events including stroke (HR, 
0.86; 95% CI, 0.77-0.97; p=0.01) when 
compared to no AHRE; long AHREs were 
associated with incident clinical events (HR, 
1.68; 95% CI, 1.49-1.88; p<0.001) and stroke 
or TIA (HR, 1.51; 95% CI, 1.03–2.21; p=0.03)
Conclusion 
Patients with AHREs exceeding 5 minutes in 
duration are more than twice as likely to die 
or have a stroke and 6 times as likely to 
develop atrial fi brillation
Thromboembolism risk is a quantitative 
function of AHRE burden
AHRE burden ≥5.5 h on any of 30 prior days 
doubled thromboembolism risk
Subclinical atrial tachyarrhythmias, without 
clinical AF, occurred frequently in patients with 
pacemakers and were associated with a 
signifi cantly increased risk of ischaemic stroke 
or systemic embolism
Intermittent anticoagulation based on 
remotely detected AHRE did not prevent 
thromboembolism
Daily AHRE burden is associated with an 
increased risk of thromboembolism even 
after adjustment for anticoagulant use and 
CHADS2 score
Adjudicated short AHREs (terminating within 
a single electrogram) were not associated with 
increased risk of clinical events when 
compared to no AHRE
Long AHREs (extending beyond a single 
electrogram) were associated with an 
increased incidence of stroke
AF = atrial fibrillation, AHRE = atrial high rate episode, ASSERT = asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial 
pacing trial, AT = atrial tachycardia,  CI = confidence interval, HR = hazard ratio, ICD = implantable cardioverter-defibrillator, IMPACT = multicenter, randomised study of 
anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and resynchronisation devices, MOST = mode selection trial, RATE = registry 
of atrial tachycardia and atrial fibrillation episodes, RCT = randomised, controlled trial, SOS AF = stroke prevention strategies based on atrial fibrillation information from implanted 
devices, TRENDS = the relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke.
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CONCLUSION
Subclinical AF is commonly recognised in patients with CIEDs 
and its relationship to systemic thromboembolism and 
ischaemic stroke presents a significant clinical management 
dilemma. Given the lack of standardised and validated AF 
detection algorithms, at this stage it behooves the clinician to 
review the intracardiac recordings. If any uncertainty exists, in 
concordance with recent ESC guidelines, acquiring additional 
surface ECG monitoring to confirm that the recorded AHRE 
is a veritable atrial tachyarrhythmia is crucial.(31) Once AF is 
diagnosed, a logical methodology to patient-specific interven-
tion is necessary and we propose the following approach 
(Figure 4).(47)
In summary, despite subtle differences in design, all studies 
presently confirm that device-detected AF positively correlates 
with thromboembolic stroke, especially in patients with 
additional stroke risk factors (Table 1).(7,25,32,33,35,41,46) Clinical risk 
prediction scores, such as CHADS2, have been studied in this 
population and demonstrate value in supporting clinical 
decisions.(33,35) Uncertainty still exists regarding the exact 
burden of AF that portends the highest risk, yet a minimum 
threshold associated with clinically events may be in the range 
of 5 or 6 minutes.(7,25,33,35,41) The detection of shorter episodes 
should not be ignored as these herald a risk for developing a 
more significant AF burden over time and further study is 
required to identify stroke risk associated with these events.(41) 
It is also striking that the majority of AF appears not to be linked 
with thromboembolic events in a temporal manner, suggesting 
that atrial arrhythmias are markers of a propensity towards 
stroke as opposed to a direct etiology of left atrial thrombus.
A reduction in stroke risk with the use of anticoagulation has 
yet to be demonstrated in the subclinical device-detected AF 
population and several trials are currently underway to address 
this question. While awaiting further data, the excess stroke risk 
in these patients should not go unheeded. Recent data suggests 
an excess stroke risk in patients with more than 24 hours of 
continuous AF even when controlling for other stroke risk 
factors.(34) We would recommend utilising clinical judgement to 
balance the risk of the risk of bleeding with initiation of systemic 
anticoagulation with the thromboembolism based on higher AF 
burden and presence of additional risk factors. 
Additional research is imperative in order to guide stand-
ardisation of AF detection algorithms and criteria for stroke 
prevention by exploiting the evolving technology of implantable 
devices. In addition to stroke prevention, the detection of 
AF should draw attention to the arrhythmia, its consequences 
and its comorbidities – prompting clinicians to review rate and 
rhythm control strategies as well as optimisation of cardio-
vascular risk factors.
Conflict of interest: none declared.
REFERENCES
1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and 
implantable cardioverter-defibrillators: calendar year 2009: A world society 
of arrhythmia's project. Pacing and clinical electrophysiology: PACE 
2011;34:1013-27.
2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of 
atrial fibrillation: A global burden of disease 2010 study. Circulation 
2014;129:837-47.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial 
fibrillation in Olmsted County, Minnesota, 1980 - 2000, and implications on 
the projections for future prevalence. Circulation 2006;114:119-25.
4. Chamberlain AM, Gersh BJ, Alonso A, et al. Decade-long trends in atrial 
fibrillation incidence and survival: a community study. The American journal 
of medicine 2015;128:260-7 e1.
5. Xiong Q, Proietti M, Senoo K, et al. Asymptomatic versus symptomatic atrial 
fibrillation: A systematic review of age/gender differences and cardiovascular 
outcomes. International journal of cardiology 2015;191:172-7.
6. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown 
atrial fibrillation. A systematic review. Thrombosis and haemostasis 2013;
110:213-22.
7. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and 
risk for stroke: an analysis of >10 000 patients from the SOS AF project 
(Stroke prevention Strategies based on atrial fibrillation information from 
implanted devices). European heart journal 2014;35:508-16.
8. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, 
atrial fibrillation, and thromboembolism: Mechanistic links and clinical 
inferences. Journal of the American College of Cardiology 2015;65:2239-51.
9. Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of 
cardiovascular disease, renal disease, and death: Systematic review and 
meta-analysis. Bmj 2016;354:i4482.
10. Mahida S. Transcription factors and atrial fibrillation. Cardiovasc Res 2014;
101:194-202.
11. Eckstein J, Verheule S, de Groot NM, et al. Mechanisms of perpetuation of 
atrial fibrillation in chronically dilated atria. Progress in biophysics and 
molecular biology 2008;97:435-51.
12. Teh AW, Kistler PM, Lee G, et al. Long-term effects of catheter ablation for 
lone atrial fibrillation: Progressive atrial electroanatomic substrate remod-
eling despite successful ablation. Heart rhythm: The official journal of the 
Heart Rhythm Society 2012;9:473-80.
13. Tsang TS, Abhayaratna WP, Barnes ME, et al. Prediction of cardiovascular 
outcomes with left atrial size: is volume superior to area or diameter? 
Journal of the American College of Cardiology 2006;47:1018-23.
14. Tsang TS, Barnes ME, Gersh BJ, et al. Left atrial volume as a morpho-
physiologic expression of left ventricular diastolic dysfunction and relation 
to cardio-vascular risk burden. The American journal of cardiology 2002;
90:1284-9.
15. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes 
with aging in patients with lone atrial fibrillation: A 30-year follow-up study. 
Circulation 2007;115:3050-6.
16. Kopecky SL, Gersh BJ, McGoon MD, et al. Lone atrial fibrillation in elderly 
persons: A marker for cardiovascular risk. Archives of internal medicine 
1999;159:1118-22.
17. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial 
tachyarrhythmias, cerebrovascular events, and systemic emboli based on 
stored device data: A subgroup analysis of TRENDS. Heart rhythm: The 
official journal of the Heart Rhythm Society 2011;8:1416-23.
18. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between 
subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094-9.
19. Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events 
by continuous home monitoring: Clinical significance in the heart failure-
cardiac resynchronisation therapy population. Europace: European pacing, 
arrhythmias, and cardiac electrophysiology: Journal of the working groups 
on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of 
the European Society of Cardiology 2012;14:230-7.
95
20
17
Vo
lu
m
e 
14
 N
um
be
r 2
38. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional 
burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: 
Findings from the Global Burden of Disease Study 2010. The Lancet Global 
health 2013;1:e259-81.
39. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial 
fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: 
American College of chest physicians evidence-based clinical practice 
guidelines. Chest 2012;141:e531S-75S.
40. Turakhia MP, Ziegler PD, Schmitt SK, et al. Atrial fibrillation burden and 
short-term risk of stroke: Case-crossover analysis of continuously recorded 
heart rhythm from cardiac electronic implanted devices. Circulation 
arrhythmia and electrophysiology 2015;8:1040-7.
41. Swiryn S, Orlov MV, Benditt DG, et al. Clinical implications of brief device-
detected atrial tachyarrhythmias in a cardiac rhythm management device 
population: Results from the registry of atrial tachycardia and atrial fibrillation 
episodes. Circulation 2016;134:1130-40.
42. Todd D, Hernandez-Madrid A, Proclemer A, et al. How are arrhythmias 
detected by implanted cardiac devices managed in Europe? Results of the 
European heart rhythm association survey. Europace: European pacing, 
arrhythmias, and cardiac electrophysiology: Journal of the working groups on 
cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the 
European Society of Cardiology 2015;17:1449-53.
43. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying 
atrial fibrillation. The New England journal of medicine 2014;370:2478-86.
44. Healey JS, Martin JL, Duncan A, et al. Pacemaker-detected atrial fibrillation in 
patients with pacemakers: Prevalence, predictors, and current use of oral 
anticoagulation. The Canadian journal of cardiology 2013;29:224-8.
45. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally 
detected ambulatory atrial fibrillation. Thrombosis and haemostasis 2014;
112:276-86.
46. Martin DT, Bersohn MM, Waldo AL, et al. Randomised trial of atrial 
arrhythmia monitoring to guide anticoagulation in patients with implanted 
defibrillator and cardiac resynchronisation devices. European heart journal 
2015;36:1660-8.
47. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in 
patients with atrial fibrillation: Emerging diagnostic and therapeutic options. 
Executive summary of the report from the 3rd AFNET/EHRA consensus 
conference. Thrombosis and haemostasis 2011;106:1012-9.
20. Holmes DR Jr., Kar S, Price MJ, et al. Prospective randomised evaluation of 
the Watchman left atrial appendage closure device in patients with atrial 
fibrillation versus long-term warfarin therapy: The PREVAIL trial. Journal of 
the American College of Cardiology 2014;64:1-12.
21. Mahajan R, Brooks AG, Sullivan T, et al. Importance of the underlying 
substrate in determining thrombus location in atrial fibrillation: Implications 
for left atrial appendage closure. Heart 2012;98:1120-6.
22. Vasamreddy CR, Dalal D, Dong J, et al. Symptomatic and asymptomatic atrial 
fibrillation in patients undergoing radiofrequency catheter ablation. Journal 
of cardiovascular electrophysiology 2006;17:134-9.
23. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless 
implantable cardiac monitor in detecting and quantifying atrial fibrillation 
results of the XPECT Trial. Circ-Arrhythmia Elec 2010;3:141-U44.
24. Sanders P, Purerfellner H, Pokushalov E, et al. Performance of a new atrial 
fibrillation detection algorithm in a miniaturised insertable cardiac monitor: 
Results from the reveal LINQ usability study. Heart rhythm: The official 
journal of the Heart Rhythm Society 2016;13:1425-30.
25. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes 
detected by pacemaker diagnostics predict death and stroke: Report of the 
atrial diagnostics ancillary study of the Mode Selection Trial (MOST). 
Circulation 2003;107:1614-9.
26. Seidl K, Meisel E, VanAgt E, et al. Is the atrial high rate episode diagnostic 
feature reliable in detecting paroxysmal episodes of atrial tachyarrhythmias? 
Pacing and clinical electrophysiology: PACE 1998;21:694-700.
27. Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhyth-
mias from the automated analysis of data stored in the DDD pacemakers of 
617 patients: the AIDA study. The AIDA Multicenter Study Group. 
Automatic interpretation for diagnosis assistance. Pacing and clinical 
electrophysiology: PACE 1998;21:250-5.
28. Kaufman ES, Israel CW, Nair GM, et al. Positive predictive value of device-
detected atrial high-rate episodes at different rates and durations: An analysis 
from ASSERT. Heart rhythm: The official journal of the Heart Rhythm 
Society 2012;9:1241-6.
29. Israel CW, Neubauer H, Olbrich HG, et al. Incidence of atrial tachyarrhyth-
mias in pacemaker patients: Results from the balanced evaluation of atrial 
tachyarrhythmias in stimulated patients (BEATS) study. Pacing and clinical 
electrophysiology: PACE 2006;29:582-8.
30. Fitts SM, Hill MR, Mehra R, et al. High rate atrial tachyarrhythmia detections 
in implantable pulse generators: Low incidence of false-positive detections. 
The PA Clinical Trial Investigators. Pacing and clinical electrophysiology: 
PACE 2000;23:1080-6.
31. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS. 
European heart journal 2016;37:2893-962.
32. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial 
tachyarrhythmia burden from implantable device diagnostics and stroke 
risk: The TRENDS study. Circulation Arrhythmia and electrophysiology 
2009;2:474-80.
33. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the 
risk of stroke. The New England journal of medicine 2012;366:120-9.
34. Van Gelder IC, Healey JS, Crijns HJ, et al. Duration of device-detected 
subclinical atrial fibrillation and occurrence of stroke in ASSERT. European 
heart journal 2017.
35. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial 
fibrillation detected by continuous monitoring: crucial implications for the 
risk of thromboembolic events. Journal of cardiovascular electrophysiology 
2009;20:241-8.
36. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification 
schemes for predicting stroke: Results from the national registry of atrial 
fibrillation. Jama 2001;285:2864-70.
37. Chen JY, Zhang AD, Lu HY, et al. CHADS2 vs. CHA2DS2-VASc score in 
assessing the stroke and thromboembolism risk stratification in patients 
with atrial fibrillation: A systematic review and meta-analysis. J Geriatr 
Cardiol 2013;10:258-66.
